Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

Monday, Aprea Therapeutics Inc APRE announced that the FDA has cleared its Investigational New Drug (IND) application for APR-1051. “APR-1051 is a next-generation inhibitor of WEE1 kinase, and based on its unique characteristics, we believe it will be best in class,” said Oren Gilad, President and…#apreatherapeuticsinc #fda #orengilad #aprea #clearanceofind #enrollment
Source: Reuters: Health - Category: Consumer Health News Source Type: news